Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature ...
Harnessing the power of IgE in Oncology
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.
The company’s lead product candidate, MOv18 IgE, has successfully completed a phase I clinical trial in folate receptor alpha positive cancer patients. This is the world’s first IgE drug to enter clinical trials. MOv18 IgE was found to be safe and well tolerated with early signs of clinical activity seen.
Epsilogen has constructed a novel and proprietary pipeline of anti-cancer IgE and IgE-derivative antibodies with enhanced functionality.